This trial will compare how effective amivantamab is at treating NSCLC with EGFR Exon 20ins mutations, compared to chemotherapy alone. The metric for success is progression-free survival (PFS).
1 Primary · 14 Secondary · Reporting Duration: Up to 48 months
2 Treatment Groups
Arm B: Chemotherapy Alone
1 of 2
Arm A: Amivantamab + Chemotherapy
1 of 2
308 Total Participants · 2 Treatment Groups
Primary Treatment: Amivantamab · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
- 2020. "A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04538664.
Frequently Asked Questions
Are there any slots open for this research project?
"That is correct. The listing on clinicaltrials.gov currently includes this trial, which was first posted on October 13th 2020 and last updated November 9th 2020. They are seeking 300 participants total, across 18 different sites." - Anonymous Online Contributor
How many total patients are being included in this experiment?
"To move forward, this clinical trial needs 300 patients that meet the pre-specified inclusion criteria. Luckily, patients can enroll at Texas Oncology Pa in Tyler, Texas or Pacific Shores Medical Group in Long Beach, California." - Anonymous Online Contributor
Has Amivantamab been used in other research trials before?
"Amivantamab was first researched in 2002 at Edinburgh Royal Hospital for Sick Children. In the last two decades, there have been 1037 completed clinical trials. As of now, 800 are recruiting patients with a significant portion being based in Tyler, Texas." - Anonymous Online Contributor
Are there any other continents where this research study is taking place?
"Currently, this trial is enrolling patients in Tyler, Texas at Texas Oncology Pa, Long Beach, California at Pacific Shores Medical Group, Orange, Georgia at University of California, Irvine, and 18 other locations." - Anonymous Online Contributor
What are some potential side effects of Amivantamab?
"Amivantamab's safety has been well-documented in Phase 3 clinical trials, and it has been shown to be effective in multiple rounds of testing. Therefore, we believe it to be a safe medication." - Anonymous Online Contributor
What are the off-label benefits of Amivantamab?
"Amivantamab is often the first intervention doctors recommend to patients. It is also an effective treatment for advanced thymoma, advanced testicular cancer, and carcinoma, neuroendocrine." - Anonymous Online Contributor